

## Security Health Plan policy review – July-August 2019

Security Health Plan reviews medical policies on a monthly basis. Medical policies are found in the provider section of the Plan's public website. As we review and develop clinical criteria for our policies, providers with particular professional knowledge or clinical expertise on certain subjects are invited to provide input and opinions. Click on [policies web page](#) for more information including past monthly policy reviews.

### **Policy changes effective July 1, 2019**

#### **Policies reviewed with changes made to medical criteria:**

- Experimental and Investigational
- Abnormal Vascular Lesion Removal
- Chelation Therapy
- Electroencephalography (EEG) Procedures
- Skin Substitutes, Chemical Peels, Dermabrasions and other Skin Procedures
- TMJ Benefit Review

#### **Policies reviewed with no changes made to medical criteria:**

- Behavioral Health – AODA: Transitional Care Coverage-Medicare Advantage
- Femoro-Acetabular Surgery for Hip Impingement Syndrome
- Infuse Bone Graft (Bmp-2) Procedure
- Physical, Occupational and Speech Therapy Exclusions

#### **New Policies**

- Gamifant
- Revcovi
- Somatuline (lanreotide)

### **Policy changes effective August 1, 2019**

#### **Policies reviewed with changes made to medical criteria:**

- Bone and tendon graft substitutes and adjuncts
- Cosmetic surgery/treatments
- Gender reassignment services and surgical procedures
- Healthcheck “other services”
- Home infusion
- Intravenous iron therapy – commercial/exchange
- Intravenous iron therapy – Medicare
- Transcatheter aortic valve replacement (TAVR)
- Crysvita
- Dupilumab
- Durvalumab
- Fosnetupitant and palonosetron
- Hyaluronic acid derivatives
- Zoledronic acid